Correction: Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA)
نویسندگان
چکیده
Georgios Hadjigeorgiou, Efthimios Dardiotis, Georgios Tsivgoulis, Triantafyllos Doskas, Damianos Petrou, Nikolaos Makris, Nikolaos Vlaikidis, Thomas Thomaidis, Athanasios Kyritsis, Nikolaos Fakas, Xoulietta Treska, Clementine Karageorgiou, Stefania Sotirli, Christos Giannoulis, Dimitra Papadimitriou, Ioannis Mylonas, Evaggelos Kouremenos, George S. Vlachos, Dimitrios Georgiopoulos, Despoina Mademtzoglou, Michalis Vikelis, Elias Zintzaras
منابع مشابه
Observational Study Assessing Demographic, Economic and Clinical Factors Associated with Access and Utilization of Health Care Services of Patients with Multiple Sclerosis under Treatment with Interferon Beta-1b (EXTAVIA)
Multiple sclerosis (MS) results in an extensive use of the health care system, even within the first years of diagnosis. The effectiveness and accessibility of the health care system may affect patients' quality of life. The aim of the present study was to evaluate the health care resource use of MS patients under interferon beta-1b (EXTAVIA) treatment in Greece, the demographic or clinical fac...
متن کاملAcute Liver Dysfunction Associated With Interferon-Beta-1a (Avonex®) Use in A Young Female Patient with Relapsing-Remitting Multiple Sclerosis (RRMS)
Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...
متن کاملAccess to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study
Background While there is currently no cure for multiple sclerosis (MS), treatment with biologic diseasemodifying drugs (bDMDs) can reduce the impact of the condition on the lives of patients. In Greece, the regulatory change in the distribution system of bDMDs, limited their administration through the designated pharmacies of the National Organization for Healthcare Services Provision (EOPYY) ...
متن کاملFingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...
متن کاملEffect of the Sera of Patients with Multiple Sclerosis on Apoptosis and Nitric Oxide Production of Endothelial Cells
Background & Aims: Multiple sclerosis (MS) is one of the chronic autoimmune diseases of the central nervous system with unknown etiology. The present study aimed to investigate the apoptosis and nitric oxide (NO) production of endothelial cells treated with serum of patients with MS and response to interferon beta (IFN- ) therapy. Methods: Human umbilical vein endothelial cells were treated wit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 10 شماره
صفحات -
تاریخ انتشار 2015